The supplied source content is limited to Frontiers in Immunology website navigation and journal metadata. The explicit article title is visible: “Molecular basis of coronary artery disease–malignancy comorbidity: inflammation, immunometabolism, thrombosis, and cardio-oncology translation.” However, the article abstract, introduction, methods, results, discussion, figures, tables, and references were not present in the provided text. Therefore, no primary study data, mechanistic descriptions, or clinical recommendations could be extracted from the source delivered to this service.
Because the substantive article body was not available in the supplied source, any attempt to summarize specific molecular pathways, experimental evidence, biomarker performance, or therapeutic implications would constitute invention. All statements below are constrained to the information explicitly present in the source and to methodological recommendations for obtaining and appraising the full article.
The source includes the journal name (Frontiers in Immunology) and the article title. The site navigation and journal section listings visible on the page include general Frontiers content (About us, How we publish, Sections) and the immunology section headings. No authorship list, abstract, funding, ethical approvals, cohort descriptions, experimental methods, or results were provided in the text delivered here.
The title signals interest in several clinical and translational domains: coronary artery disease, malignancy, inflammation, immunometabolism, thrombosis, and cardio-oncology translation, but the source did not expand on these topics with data, mechanisms, or recommendations.
The article title implies exploration of molecular connections linking cardiovascular disease and cancer across four thematic areas: inflammation, immunometabolism, thrombosis, and translation into cardio-oncology practice. From the title alone a reader can infer the authors intended to address overlapping mechanisms that may contribute to comorbidity between coronary artery disease and malignancy and consider implications for translational medicine.
However, the supplied source did not present any definitions, pathway diagrams, experimental evidence, or citations supporting those topics. No information about which immune pathways, metabolic regulators, coagulation factors, or translational strategies were analyzed or recommended is available in the provided text.
These limitations preclude any evidence-based clinical interpretation or downstream recommendations based solely on the provided source.
Retrieve the full-text article directly from the publisher (Frontiers in Immunology) using the DOI or article URL. The source URL provided in the metadata should be used to access the article landing page and to download the full HTML or PDF.
On obtaining the full text, extract key elements systematically: authors, affiliations, abstract, background, objectives, methods (including cohorts or experimental systems), results (with statistics), discussion, limitations, and conclusions.
Appraise internal validity: study design, sample size, controls, reproducibility, and statistical rigor must be assessed before applying findings clinically.
Evaluate translational relevance: determine whether reported mechanisms are supported by human data, preclinical models, or both; identify candidate biomarkers or therapeutic targets and note whether clinical trials or guideline recommendations exist.
Check transparency items: funding sources, conflicts of interest, data availability, and ethical approvals should be documented and considered when weighing conclusions.
If planning to cite or implement findings, cross-reference other recent reviews and guideline statements in cardiology and oncology and confirm consistency with established evidence.
Use the full text to inform mechanistic understanding only after critical appraisal; do not change clinical care based on title alone.
If mechanistic claims appear robust and are corroborated by additional literature, consider multidisciplinary discussion (cardiology, oncology, hematology, thrombosis specialists, and immunology) before translating into practice.
For potential biomarkers or interventions described in the article, confirm that diagnostic performance, safety, and regulatory status are appropriate before clinical adoption.
Where the article proposes hypothesis-generating links, treat these as starting points for further research or for designing prospective validation studies rather than immediate clinical guidelines.
The supplied source contains only site navigation and metadata. All clinically actionable content must be obtained from the full article text on the publisher site. This rewrite preserves the original article’s topical focus as stated in the title and provides explicit, source-based guidance for obtaining and appraising the missing content. No additional molecular or clinical claims were inferred beyond those signaled by the article title because the detailed manuscript content was not reported in the provided source.